Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew Lang resigned as Chief Business Officer at Lyell Immunopharma, Inc..
- Action
- resigned
- Role
- Chief Business Officer
Exact text from the filing
On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Lyell Immunopharma, Inc. announced a restructuring with charges of $3.0 million to $4.0 million affecting West Hills manufacturing facility (approximately 73 employees).
- Type
- restructuring
- Charge
- $3.0 million to $4.0 million
- Affected area
- West Hills manufacturing facility
- Headcount
- approximately 73 employees
Exact text from the filing
On March 31, 2025, Lyell’s Board of Directors (the “Board”) approved the closure of the West Hills manufacturing facility acquired as part of Lyell’s acquisition of ImmPACT Bio in 2024. The Board also approved the reduction of the Company’s workforce in West Hills by approximately 73 employees related to such closure. In connection with these actions, the Company expects to incur aggregate expenses of between $3.0 million to $4.0 million, related to severance, benefits, payroll taxes, and other workforce reduction costs, which are expected to be recognized primarily in the second and third quarters of 2025.
View on SEC.gov